Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pituitary ACTH Hypersecretion 1Medulloblastoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Astrocytoma 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × fimepinostat × Clear all
NCT03893487 2025-07-11

PNOC016

University of California, San Francisco

Phase EARLY_PHASE1 Active not recruiting
30 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Medulloblastoma

NCT05971758 2025-07-04

Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

University of California, Los Angeles

Phase 2 Recruiting
20 enrolled
Endocrine

Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡